Richard Ulevitch
Venture Partner @ 5AM Ventures
San Francisco, United States
Richard Ulevitch is a Series B investor at 5AM Ventures in San Francisco focused on Biotechnology and Life Science. Richard Ulevitch is based out of San Francisco, California, and is the Venture Partner of 5AM Ventures. Richard previously worked at the Scripps Research Institute as a Professor and Chairman. Richard Ulevitch attended the University of Pennsylvania.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 9%
Last updated:
For AI agents: llms.txt
Industries Richard Ulevitch invests in
BiotechnologyLife ScienceTherapeuticsMedicalPharmaceutical
Stages Richard Ulevitch invests in
Series BSeries ASeries CPost-IPO Equity
Countries Richard Ulevitch invests in
United States
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 3 (27%)
- Life Science 2 (18%)
- Therapeutics 2 (18%)
- Medical 1 (9%)
- Pharmaceutical 1 (9%)
Stage
- Series B 3 (27%)
- Series A 2 (18%)
- Series C 1 (9%)
- Post-IPO Equity 1 (9%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Pulmatrix is a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is initially focused on advancing treatments for serious lung diseases, including Pulmazole, an inhaledanti-fungal for patients with ABPA, and PUR1800, a narrow spectrum kinase inhibitor in lung cancer. Pulmatrix's product candidates are based on iSPERSE™, its proprietary engineered dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by achieving optimal local drug concentrations and reducing systemic side effects to improve patient outcomes. | $10M / Post-IPO Equity / Jun 16, 2015 | ||
| Bird Rock Bio is focused on the discovery and development of novel biologic therapeutics that meet the medical and commercial needs for China’s patients and healthcare system and that have the potential to be disruptive globally. RYI-008 is a novel, extremely potent monoclonal antibody that is highly selective to IL-6, a cytokine widely implicatedin inflammation and cancer. In addition to RYI-008, RuiYi has a growing pipeline of monoclonal antibodies from its internal discovery efforts utilizing a series of the Company’s technologies, including the iCAP (intramembranous Conformation Antigen Presenting) system. Targets include a select subset of G protein coupled receptors (GPCR), where specificity in binding is critical but has proven difficult to achieve with small molecule modulators. | $15M / Series B / Mar 27, 2014 | ||
| Igenica Biotherapeutics is focused on the discovery and development of antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. They are the only biotherapeutic company that fully powers the ADC development spectrum from a clinically relevant approach to target and functional antibody discovery to ADC creation, acceleratingdevelopment and the delivery of effective therapies to patients.Founded in 2009, Igenica is led by a proven team of leaders that have demonstrated success in antibody drug discovery, clinical development and commercialization. Their leadership team has played a seminal role in six out of the 36 currently approved antibody therapeutic products.Based in Burlingame, Calif., they are well-funded by a premier team of life science investors including The Column Group, OrbiMed, 5AM Ventures and Third Rock Ventures. | $14M / Series C / Jan 28, 2014 | ||
| Igenica Biotherapeutics is focused on the discovery and development of antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. They are the only biotherapeutic company that fully powers the ADC development spectrum from a clinically relevant approach to target and functional antibody discovery to ADC creation, acceleratingdevelopment and the delivery of effective therapies to patients.Founded in 2009, Igenica is led by a proven team of leaders that have demonstrated success in antibody drug discovery, clinical development and commercialization. Their leadership team has played a seminal role in six out of the 36 currently approved antibody therapeutic products.Based in Burlingame, Calif., they are well-funded by a premier team of life science investors including The Column Group, OrbiMed, 5AM Ventures and Third Rock Ventures. | $33M / Series C / Jun 12, 2012 | ||
| Pulmatrix is a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is initially focused on advancing treatments for serious lung diseases, including Pulmazole, an inhaledanti-fungal for patients with ABPA, and PUR1800, a narrow spectrum kinase inhibitor in lung cancer. Pulmatrix's product candidates are based on iSPERSE™, its proprietary engineered dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by achieving optimal local drug concentrations and reducing systemic side effects to improve patient outcomes. | $14M / Series B / Aug 15, 2011 | ||
| Igenica Biotherapeutics is focused on the discovery and development of antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. They are the only biotherapeutic company that fully powers the ADC development spectrum from a clinically relevant approach to target and functional antibody discovery to ADC creation, acceleratingdevelopment and the delivery of effective therapies to patients.Founded in 2009, Igenica is led by a proven team of leaders that have demonstrated success in antibody drug discovery, clinical development and commercialization. Their leadership team has played a seminal role in six out of the 36 currently approved antibody therapeutic products.Based in Burlingame, Calif., they are well-funded by a premier team of life science investors including The Column Group, OrbiMed, 5AM Ventures and Third Rock Ventures. | $24M / Series B / Jun 14, 2010 | ||
| Pulmatrix is a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is initially focused on advancing treatments for serious lung diseases, including Pulmazole, an inhaledanti-fungal for patients with ABPA, and PUR1800, a narrow spectrum kinase inhibitor in lung cancer. Pulmatrix's product candidates are based on iSPERSE™, its proprietary engineered dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by achieving optimal local drug concentrations and reducing systemic side effects to improve patient outcomes. | $30.2M / Series B / Nov 02, 2009 | ||
| Bird Rock Bio is focused on the discovery and development of novel biologic therapeutics that meet the medical and commercial needs for China’s patients and healthcare system and that have the potential to be disruptive globally. RYI-008 is a novel, extremely potent monoclonal antibody that is highly selective to IL-6, a cytokine widely implicatedin inflammation and cancer. In addition to RYI-008, RuiYi has a growing pipeline of monoclonal antibodies from its internal discovery efforts utilizing a series of the Company’s technologies, including the iCAP (intramembranous Conformation Antigen Presenting) system. Targets include a select subset of G protein coupled receptors (GPCR), where specificity in binding is critical but has proven difficult to achieve with small molecule modulators. | $13M / Series A / May 14, 2009 | ||
| Pulmatrix is a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is initially focused on advancing treatments for serious lung diseases, including Pulmazole, an inhaledanti-fungal for patients with ABPA, and PUR1800, a narrow spectrum kinase inhibitor in lung cancer. Pulmatrix's product candidates are based on iSPERSE™, its proprietary engineered dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by achieving optimal local drug concentrations and reducing systemic side effects to improve patient outcomes. | $3.5M / Series A / Mar 11, 2009 | ||
| Bird Rock Bio is focused on the discovery and development of novel biologic therapeutics that meet the medical and commercial needs for China’s patients and healthcare system and that have the potential to be disruptive globally. RYI-008 is a novel, extremely potent monoclonal antibody that is highly selective to IL-6, a cytokine widely implicatedin inflammation and cancer. In addition to RYI-008, RuiYi has a growing pipeline of monoclonal antibodies from its internal discovery efforts utilizing a series of the Company’s technologies, including the iCAP (intramembranous Conformation Antigen Presenting) system. Targets include a select subset of G protein coupled receptors (GPCR), where specificity in binding is critical but has proven difficult to achieve with small molecule modulators. | $25M / Series A / Jan 07, 2009 | ||
| See all 11 investments → | |||
Co-Investors
Polaris Partners
4 deals together
Apposite Capital
3 deals together
SR One
3 deals together
The Column Group
3 deals together
Versant Ventures
3 deals together
5AM Ventures
2 deals together
About 5AM Ventures
5AM Ventures is a venture capital firm that offers seed- and early-stage investments to its clients. The company’s client portfolio consists of firms in the biopharmaceutical, life sciences, medical technology, and research instrument industries. 5AM Ventures was founded in 2002 by John Diekman and Andrew Schwab and is based in California.
5AM Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
John Diekman
Founder & Managing Partner
|
|||
Kush Parmar
Managing Partner
|
|||
Mason Freeman
Venture Partner
|
|||
|
Richard Ulevitch
Venture Partner
|
|||
Scott Rocklage
Founding Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
Health Care Investors
48,825 investors
Biotech Investors
24,243 investors
Biotechnology Investors
21,493 investors
Medical Investors
21,329 investors
Life Science Investors
7,571 investors
Health Care VC Funds
36,610 investors
Biotech VC Funds
20,947 investors
Biotechnology VC Funds
18,846 investors
Medical VC Funds
18,339 investors
FAQ
What does Richard Ulevitch invest in?
Richard Ulevitch invests primarily in Biotechnology, Life Science and Therapeutics startups, most often at Series B and Series A stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Richard Ulevitch?
Public channels for Richard Ulevitch include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Richard Ulevitch last invest?
The most recent investment recorded for Richard Ulevitch closed in Jun 2015. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
